Abstract

CORDOBA, Susana et al. Usefulness of the Sensititre YeastOne® panel to detect Candida species resistant to antifungal drugs. Rev. argent. microbiol. [online]. 2022, vol.54, n.1, pp.1-10. ISSN 0325-7541.  http://dx.doi.org/10.1016vj.ram.2021.02.002.

We evaluated the interlaboratory agreement, the essential agreement, and the cate- gorical agreement between the Sensititre YeastOne™ panel and the reference methods M27 4th Edition of the Clinical and Laboratory Standards Institute (CLSI), and the EDef 7.3.1 of the Euro- pean Committee on Antifungal Susceptibility Testing (EUCAST). We studied 67 Candida strains isolated from different clinical samples and 9 Candida strains with resistance to fluconazole and echinocandins. The highest percentage of interlaboratory agreement was observed with amp- hotericin B (96.8%), and the lowest percentage with voriconazole (77.2%). Caspofungin showed 5.8% of very major errors when compared with the CLSI reference method. For EUCAST, itraconazole, posaconazole, and anidulafungin showed high percentages of major errors: 17.6%, 18.1%, and 19.6%, respectively. Sensititre YeastOne™ is a reliable alternative, and easy to perform for detecting Candida species resistant to antifungal drugs, with some limitations for echinocandins. Results are comparable to those of the reference methods.

Keywords : Sensititre; Candida spp.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )